295 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
INCY Incyte Corporation $67.04 $14.25B N/A
Article Searches
Incyte's Application for Pemigatinib Gets EMA's Validation http://www.zacks.com/stock/news/708239/incytes-application-for-pemigatinib-gets-emas-validation?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-708239 Jan 08, 2020 - The EMA endorses Incyte's (INCY) MAA for pemigatinib to treat locally advanced/metastatic cholangiocarcinoma with a FGFR2 fusion that is relapsed or refractory post minimum one line of systemic therapy.
Biotech Stock Roundup: Updates From INCY & EXEL, APLS & LIFE Surge on Positive Data http://www.zacks.com/stock/news/708127/biotech-stock-roundup-updates-from-incy-exel-apls-life-surge-on-positive-data?cid=CS-ZC-FT-analyst_blog|stock_roundup-708127 Jan 08, 2020 - A low-key week for the biotech sector, with a few pipeline and regulatory updates.
Company News For Jan 6, 2020 http://www.zacks.com/stock/news/704772/company-news-for-jan-6-2020?cid=CS-ZC--corporate_summary-704772 Jan 06, 2020 - Companies In The News Are: CANF, LW, INCY, NOVN
INCY: BMO Capital Markets reits Market Perform https://www.briefing.com/in-depth-analysis/Content/Article?ArticleId=UD20200103142954 Jan 03, 2020 - BMO Capital Markets issues rating change for INCY
INCY, LNDC among premarket losers https://seekingalpha.com/news/3529502-incy-lndc-among-premarket-losers?utm_source=feed_news_all&utm_medium=referral Jan 03, 2020 - Novan (NASDAQ:NOVN) -73% on failed SB206 study.DPW Holdings (NYSEMKT:DPW) -30% on doubts over FINRA approval of proposed acquisitions.Landec (NASDAQ:LNDC) -15% on Q2 earnings.Mereo BioPharma Group (NA
A $20 Billion Sweet Spot in Biotech https://www.fool.com/investing/2019/12/28/a-20-billion-sweet-spot-in-biotech.aspx?source=iedfolrf0000001 Dec 28, 2019 - Few biotech companies ever reach that valuation, and if they do, you should snap them up for your portfolio.
Has Incyte (INCY) Outpaced Other Medical Stocks This Year? http://www.zacks.com/stock/news/686067/has-incyte-incy-outpaced-other-medical-stocks-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-686067 Dec 24, 2019 - Is (INCY) Outperforming Other Medical Stocks This Year?
Here's Why Momentum Investors Will Love Incyte (INCY) http://www.zacks.com/stock/news/673535/heres-why-momentum-investors-will-love-incyte-incy?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_10-673535 Dec 16, 2019 - Does Incyte (INCY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Incyte's NDA for Pemigatinib Gets FDA's Priority Review Tag http://www.zacks.com/stock/news/644810/incytes-nda-for-pemigatinib-gets-fdas-priority-review-tag?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-644810 Nov 28, 2019 - The FDA accepts and grants priority review to Incyte's (INCY) new drug application for pemigatinib as a second-line treatment for patients with FGFR2 translocated cholangiocarcinoma.
Merck's Keytruda Gets Nod in China for Difficult Lung Cancer http://www.zacks.com/stock/news/643382/mercks-keytruda-gets-nod-in-china-for-difficult-lung-cancer?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-643382 Nov 27, 2019 - Merck (MRK) receives the third approval of Keytruda for first-line non-small cell lung cancer patient population in China.

Pages: 123456...30

Page 1>